Work Here?
Overview
Alvotech develops and manufactures biosimilar medicines, which are lower-cost versions of biologic drugs used to treat a range of diseases. Its biosimilars are produced through a vertically integrated process, controlling cell line development, manufacturing, and final product steps to ensure quality and efficiency. The company differentiates itself by owning and coordinating the full value chain, enabling tighter cost control, scalable production, and faster delivery of biosimilars to global markets. Alvotech aims to improve lives by making biologic medicines more accessible and affordable, continually evaluating new pipeline opportunities to expand its portfolio and revenue streams.
About Alvotech
Industries
Industrial & Manufacturing
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Reykjavík, Iceland
Founded
2013
Get referred to Alvotech
See people who can refer or advise you
Simplify's Take
What believers are saying
- FDA accepted AVT16 on June 8, 2026; EMA validated AVT16 and AVT80.
- Alvotech reaffirmed 2026 revenue guidance of $650 million to $700 million on August 19, 2026.
- BofA initiated coverage in August 2026, citing over ten programs and roughly $200 billion LOE.
What critics are saying
- Janssen sued Alvotech on June 19, 2026 over AVT05 patents in Virginia.
- FDA labeled Reykjavik inspection VAI on July 29, 2026 after prior 2025 CRLs.
- Any another manufacturing failure kills Q4 2026 launches and threatens the 2027 financing window.
What makes Alvotech unique
- Alvotech’s Reykjavik vertical integration controls cell-line development, manufacturing, and commercial supply.
- Five biosimilars already sell globally: Humira, Stelara, Simponi, Eylea, Prolia/Xgeva.
- Lotus deal on August 21, 2026 gives Alvotech direct U.S. commercialization participation.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$2.4B
Above
Industry Average
Funded Over
15 Rounds
Benefits
Wellness Program
Home Office Stipend
Phone/Internet Stipend
Commuter Benefits
Company Social Events
Professional Development Budget
Flexible Work Hours
Stock Price
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 1%2 year growth
↑ 0%BofA Securities initiated coverage of Alvotech with a "buy" rating and $7 price target, well above the stock's $4.43 Monday close. The biosimilar developer recently cleared a regulatory hurdle when the FDA closed its inspection of the company's Reykjavik manufacturing facility. Shares rose 2.7% in pre-market trading. BofA's target is based on discounted cash flow analysis using a 10% discount rate and 1% terminal growth. The firm said Alvotech achieved its first profitable year in 2025 and has assembled a pipeline of over 10 programmes targeting a roughly $200 billion biologic loss-of-exclusivity opportunity through 2033. Near-term catalysts include US launches of biosimilars for Simponi, Eylea SD, and Entyvio. BofA expects future launches to drive scale and margin expansion, with commercialisation costs primarily borne by partners.
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets. * 1 hr ago REYKJAVIK, Iceland, Aug. 21, 2026 (GLOBE NEWSWIRE) - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical (TWSE Stock Code: 1795) covering two of Alvotech's candidates in the United States and selected Asian markets: AVT34, a proposed biosimilar to Imfinzi(R)(durvalumab), and AVT87, a proposed biosimilar to Hemlibra(R)(emicizumab). Imfinzi(R) is an oncology biologic used in the treatment of multiple cancers, which generated global sales of approximately $6.1 billion in 2025[1]. Hemlibra(R) is a biologic for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A that generated global sales of approximately CHF4.8 billion (approximately $5.8 billion) in 2025[2]. Under a semi-exclusive agreement in the United States, Alvotech retains the right to commercialize both products directly alongside Lotus, while Lotus will commercialize the products through Alvogen, its U.S.-based wholly owned subsidiary. Alvotech will retain responsibility for product development, and for obtaining and maintaining marketing authorizations in the United States, and will serve as the exclusive supplier of the products for all markets. In Asia, Lotus will have exclusive commercialization rights in eight selected markets: South Korea, Taiwan, Thailand, Vietnam, the Philippines, Singapore, Hong Kong and Malaysia. Lotus will be responsible for local regulatory submissions and commercialization in these markets. The agreement has a potential value to Alvotech of up to approximately $150 million in upfront and milestone payments, in addition to ongoing revenues from the supply of commercial product. "This agreement represents an important evolution of Alvotech's commercial strategy," said Lisa Graver, Chief Executive Officer of Alvotech. "For the first time, we will have the opportunity to participate directly in the future commercialization of our products in the United States, allowing us to retain a greater share of the value we create through our development and manufacturing platform. At the same time, our partnership with Lotus extends the potential reach of these two important pipeline assets across key Asian markets. We look forward to working together to bring these medicines to patients and broaden access to high-quality biologics." "We are pleased to partner with Alvotech on two important biosimilar candidates that meaningfully advance Lotus' global growth strategy," said Petar Vazharov, Chief Executive Officer of Lotus. "By combining Alvotech's integrated biosimilar development and manufacturing capabilities with Alvogen's established U.S. commercial platform and Lotus's deep market presence across Asia, we are building a strong foundation for the future commercialization of AVT34 and AVT87 across key global markets. These candidates expand the scale and reach of our biosimilar portfolio in oncology and rare diseases, and reinforces our commitment to broadening access to high-quality medicines." Imfinzi(R) and Hemlibra(R) are registered trademarks and the property of their respective owners. | [1)] | [AstraZeneca PLC. (2026). Annual report on Form 20-F for the fiscal year ended December 31, 2025. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm] | | [2)] | [Roche, Finance Report 2025, F. Hoffmann-La Roche Ltd, https://assets.roche.com/f/176343/x/fca190f63e/fb25e.pdf] | | / | / | Benedikt Stefansson Sarah MacLeod Dr. Balaji V Prasad Benedikt Stefansson About Alvotech Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira(R)(adalimumab), Stelara(R)(ustekinumab), Simponi(R)(golimumab), Eylea(R)(aflibercept) and Prolia(R)/Xgeva(R)(denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release. Forward Looking Statements Certain statements in this communication may be considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech's expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech's control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.
Alvotech reported first-half revenue of $212 million, down from $306 million a year earlier, as manufacturing slowed during facility and quality-system improvements at its Reykjavik site. Adjusted EBITDA fell to $47 million from $54 million in the prior-year period. CEO Lisa Graver said the decline did not reflect weaker demand for the company's biosimilars. Production returned to planned levels near the end of Q2, and management reaffirmed 2026 guidance of $650 million–$700 million in revenue and $180 million–$220 million in adjusted EBITDA. Alvotech raised approximately $240 million through a $165 million equity offering and a term loan facility of up to $75 million. The FDA closed its Reykjavik inspection with a VAI classification, with potential US approvals expected in Q4 2026.
Alvotech (ALVO) Q2 2026 earnings: mixed financials. Aug 20, 2026 Market News FMPAlvotech (ALVO) Q2 2026 earnings: mixed financials. Alvotech (NASDAQ:ALVO) Q2 2026 earnings: mixed financial performance in biosimilar market. * Alvotech (NASDAQ:ALVO), a global biotechnology company specializing in biosimilar medicines, reported a mixed Q2 2026, missing analyst consensus for earnings per share but surpassing revenue forecasts. * The company's financial health shows challenges, including a negative Price-to-Earnings (P/E) ratio and Debt-to-Equity ratio, alongside a declining cash balance. * Despite beating quarterly revenue estimates, the biosimilar developer experienced a significant year-over-year decline in sales within the competitive Medical - Biomedical and Genetics industry. Alvotech is a global biotechnology company that specializes in the development and manufacturing of biosimilar medicines. It operates within the competitive Medical - Biomedical and Genetics industry. On August 19, 2026, the company announced its financial results for the second quarter, presenting a mixed performance to investors. The company reported a loss per share of -$0.11, missing the consensus analyst estimate of a -$0.05 loss. As highlighted by Zacks.com, this result is a sharp decline from earnings of $0.14 per share in the same quarter last year. This marks the fourth consecutive quarter in which Alvotech has not surpassed consensus earnings-per-share estimates. On a more positive note, Alvotech posted quarterly revenue of $106 million, which surpassed the analyst forecast of $103 million. While this figure beat the Zacks Consensus Estimate by 6.72%, it represents a significant decrease from the $173.34 million in revenue reported in the second quarter of the previous year. Looking at stock valuation, the company has a Price-to-Sales (P/S) ratio of 2.41. Alvotech also has a negative Price-to-Earnings (P/E) ratio of -14.03. A negative P/E ratio indicates that the company has experienced a net loss over the past 12 months rather than generating a profit for its shareholders. From a balance-sheet perspective, Alvotech's negative Debt-to-Equity ratio of -5.16 suggests that the company has negative shareholders' equity, where total liabilities exceed total assets. The company's cash balance also declined to $142.80 million. Its current ratio, a measure of short-term financial health, stands at 1.76. Market news and analyst rating coverage Stuart Mooney covers market news and analyst activity for the FMP blog, including price-target revisions, upgrades and downgrades, and company developments. The focus is on clear, factual summaries of market-moving events grounded in financial data. Financial data for every need. Real-time quotes and 30+ years of historical data, including prices, fundamentals, and insider transactions - all accessible via API. Stock Screener 2017-2026 (C) FMP
Alvotech (NASDAQ:ALVO) shares up 13.5% - here's what happened. July 29, 2026 Key points. * Alvotech shares climbed 13.5% in mid-day trading, reaching $3.27 and last trading at $3.5180, though volume was 72% below its average. * Analyst sentiment remains mixed: two analysts rate the stock Buy, two Hold and two Sell, resulting in an overall "Hold" rating and an average price target of $7.60. * Alvotech reported quarterly revenue of $105.9 million and a loss of $0.09 per share, while maintaining negative profitability metrics, including a 14.36% net margin. * MarketBeat previews the top five stocks to own by August 1st. Alvotech (NASDAQ:ALVO - Get Free Report)'s stock price rose 13.5% during mid-day trading on Wednesday. The company traded as high as $3.27 and last traded at $3.5180. 166,172 shares traded hands during mid-day trading, a decline of 72% from the average daily volume of 602,957 shares. The stock had previously closed at $3.10. Wall Street Analyst weigh in. Several research analysts recently commented on ALVO shares. Weiss Ratings downgraded Alvotech from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, June 9th. Wall Street Zen cut shares of Alvotech from a "hold" rating to a "sell" rating in a research note on Saturday, May 23rd. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Alvotech presently has an average rating of "Hold" and an average target price of $7.60. Alvotech stock up 15.0%. The business has a 50-day moving average price of $3.55 and a 200-day moving average price of $3.88. The firm has a market capitalization of $1.08 billion, a PE ratio of -14.23 and a beta of 0.19. Alvotech (NASDAQ:ALVO - Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($0.09) EPS for the quarter. The company had revenue of $105.90 million during the quarter. Alvotech had a negative net margin of 14.36% and a negative return on equity of 11.92%. On average, equities research analysts anticipate that Alvotech will post 0.05 earnings per share for the current year. Institutional inflows and outflows. Institutional investors and hedge funds have recently modified their holdings of the company. ProShare Advisors LLC grew its holdings in shares of Alvotech by 24.0% in the fourth quarter. ProShare Advisors LLC now owns 13,826 shares of the company's stock valued at $71,000 after purchasing an additional 2,675 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Alvotech by 25.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,211 shares of the company's stock worth $78,000 after purchasing an additional 3,110 shares during the period. Magnetar Financial LLC acquired a new position in Alvotech in the 3rd quarter valued at about $86,000. Orion Porfolio Solutions LLC acquired a new position in Alvotech in the 3rd quarter valued at about $92,000. Finally, Stifel Financial Corp purchased a new stake in shares of Alvotech in the 4th quarter valued at approximately $108,000. About Alvotech. Alvotech NASDAQ: ALVO is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high-quality, cost-effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in-house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers. Discover more Stock Screener Tool MarketBeat All Access Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara). This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Alvotech, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alvotech wasn't on the list. While Alvotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates.
There are no jobs for Alvotech right now.
Find jobs on Simplify and start your career today
About Alvotech
Industries
Industrial & Manufacturing
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Reykjavík, Iceland
Founded
2013
There are no jobs for Alvotech right now.
Find jobs on Simplify and start your career today